{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:29:50Z","timestamp":1766579390032},"reference-count":54,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.medcli.2019.11.003","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T13:30:02Z","timestamp":1578663002000},"page":"308-314","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nuevos tratamientos en la hipertrigliceridemia y en la hiperquilomicronemia"],"prefix":"10.1016","volume":"154","author":[{"given":"Juan de Dios","family":"Garc\u00eda D\u00edaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2019.11.003_bib0275","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2014.09.042","article-title":"Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease","volume":"64","author":"Rosenson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2019.11.003_bib0280","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/clinchem\/39.7.1495","article-title":"Variability of lipid measurements: Relevance for the clinician","volume":"39","author":"Schectman","year":"1993","journal-title":"Clin Chem"},{"key":"10.1016\/j.medcli.2019.11.003_bib0285","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1520-037X.2002.00563.x","article-title":"Intraindividual variability of children's blood lipid and lipoprotein concentrations: A review","volume":"5","author":"Tolfrey","year":"2002","journal-title":"Prev Cardiol"},{"key":"10.1016\/j.medcli.2019.11.003_bib0290","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nrcardio.2013.140","article-title":"Demystifying the management of hypertriglyceridaemia","volume":"10","author":"Watts","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.medcli.2019.11.003_bib0295","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1101\/gad.209296.112","article-title":"Biochemistry and pathophysiology of intravascular and intracellular lipolysis","volume":"27","author":"Young","year":"2013","journal-title":"Genes Dev"},{"key":"10.1016\/j.medcli.2019.11.003_bib0300","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bbalip.2011.10.007","article-title":"Allelic and phenotypic spectrum of plasma triglycerides","volume":"1821","author":"Johansen","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.medcli.2019.11.003_bib0305","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.medcli.2019.11.003_bib0310","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jacl.2015.03.009","article-title":"JCL Roundtable: Hypertriglyceridemia due to defects in lipoprotein lipase function","volume":"9","author":"Brown","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.medcli.2019.11.003_bib0315","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11883-017-0667-9","article-title":"Genetics of triglycerides and the risk of atherosclerosis","volume":"19","author":"Dron","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.medcli.2019.11.003_bib0320","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is most often multifactorial: A narrative review of causes and treatment","volume":"170","author":"Chait","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2019.11.003_bib0325","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/js.2019-00129","article-title":"Very severe hypertriglyceridemia in a large US County Health Care System: Associated conditions and management","volume":"3","author":"Esparza","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.medcli.2019.11.003_bib0330","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MOL.0b013e3283471972","article-title":"Genetic bases of hypertriglyceridemic phenotypes","volume":"22","author":"Johansen","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.medcli.2019.11.003_bib0335","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an \u2018FCS score\u2019","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.medcli.2019.11.003_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","article-title":"Diagnostic algorithm for familial chylomicronemia syndrome","volume":"23","author":"Stroes","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.medcli.2019.11.003_bib0345","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11886-016-0745-6","article-title":"Triglyceride-rich lipoproteins and remnants: Targets for therapy?","volume":"18","author":"Dallinga-Thie","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.medcli.2019.11.003_bib0350","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: New insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.medcli.2019.11.003_bib0355","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11883-016-0623-0","article-title":"HDL as a causal factor in atherosclerosis: Insights from human genetics","volume":"18","author":"Brunham","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.medcli.2019.11.003_bib0360","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cca.2014.01.015","article-title":"Postprandial hypertriglyceridemia as a coronary risk factor","volume":"431","author":"Boren","year":"2014","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.medcli.2019.11.003_bib0365","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/dom.13537","article-title":"Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol","volume":"21","author":"Nichols","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.medcli.2019.11.003_bib0370","article-title":"Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis","author":"Chyzhyk","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.medcli.2019.11.003_bib0375","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2018.12.019","article-title":"Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia","volume":"283","author":"Paquette","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.medcli.2019.11.003_bib0380","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12328-018-0881-1","article-title":"Hypertriglyceridemia-induced pancreatitis: Updated review of current treatment and preventive strategies","volume":"11","author":"Rawla","year":"2018","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.medcli.2019.11.003_bib0385","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.clnu.2017.09.028","article-title":"A systematic review of the epidemiology, pathophysiology and current management of hyperlipidaemic pancreatitis","volume":"37","author":"Adiamah","year":"2018","journal-title":"Clin Nutr"},{"key":"10.1016\/j.medcli.2019.11.003_bib0390","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archinte.166.3.285","article-title":"Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: A meta-analysis of randomized controlled trials","volume":"166","author":"Nordmann","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.medcli.2019.11.003_bib0395","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.amjcard.2016.02.011","article-title":"A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia","volume":"117","author":"Karlson","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.medcli.2019.11.003_bib0400","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jacl.2018.01.008","article-title":"Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Sahebkar","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.medcli.2019.11.003_bib0405","first-page":"CD009753","article-title":"Fibrates for primary prevention of cardiovascular disease events","volume":"11","author":"Jakob","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2019.11.003_bib0410","first-page":"CD009580","article-title":"Fibrates for secondary prevention of cardiovascular disease and stroke","volume":"10","author":"Wang","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2019.11.003_bib0415","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1368-5031.2006.00882.x","article-title":"FIELDS of dreams, fields of tears: A perspective on the fibrate trials","volume":"60","author":"Wierzbicki","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.medcli.2019.11.003_bib0420","first-page":"CD009744","article-title":"Niacin for primary and secondary prevention of cardiovascular events","volume":"6","author":"Schandelmaier","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2019.11.003_bib0425","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12944-017-0541-3","article-title":"Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: A review","volume":"16","author":"Oscarsson","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.medcli.2019.11.003_bib0430","first-page":"CD003177","article-title":"Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease","volume":"7","author":"Abdelhamid","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2019.11.003_bib0435","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2019.11.003_bib0440","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11883-019-0762-1","article-title":"New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease","volume":"21","author":"Preston","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.medcli.2019.11.003_bib0445","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","article-title":"Omega-3 fatty acids for the management of hypertriglyceridemia: A science advisory from the american heart association","volume":"140","author":"Skulas-Ray","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2019.11.003_bib0450","doi-asserted-by":"crossref","first-page":"4721357","DOI":"10.1155\/2018\/4721357","article-title":"Management of hypertriglyceridemia induced acute pancreatitis","volume":"2018","author":"Garg","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.medcli.2019.11.003_bib0455","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/jcm8071085","article-title":"The future of lipid-lowering therapy","volume":"8","author":"Zwol","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.medcli.2019.11.003_bib0460","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12944-015-0006-5","article-title":"Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome","volume":"14","author":"Meyers","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.medcli.2019.11.003_bib0465","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2217\/fca-2016-0059","article-title":"PPARs: Regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-alpha","volume":"13","author":"Han","year":"2017","journal-title":"Future Cardiol"},{"key":"10.1016\/j.medcli.2019.11.003_bib0470","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2217\/fca-2017-0019","article-title":"PPARs: Regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-beta\/delta and PPAR-gamma","volume":"13","author":"Han","year":"2017","journal-title":"Future Cardiol"},{"key":"10.1016\/j.medcli.2019.11.003_bib0475","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jcp.25804","article-title":"The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice","volume":"233","author":"Derosa","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.medcli.2019.11.003_bib0480","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12933-019-0864-7","volume":"18","author":"Fruchart","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.medcli.2019.11.003_bib0485","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.medcli.2019.11.003_bib0490","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2014.3321","article-title":"Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type2 diabetes mellitus: The AleCardio randomized clinical trial","volume":"311","author":"Lincoff","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2019.11.003_bib0495","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist-saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.medcli.2019.11.003_bib0500","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc11-0093","article-title":"Effects of the new dual PPAR alpha\/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism","volume":"34","author":"Cariou","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.medcli.2019.11.003_bib0505","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.atherosclerosis.2011.10.029","article-title":"Effects of the PPAR-delta agonist MBX-8025 on atherogenic dyslipidemia","volume":"220","author":"Choi","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.medcli.2019.11.003_bib0510","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosissup.2017.05.003","article-title":"The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia","volume":"30","author":"Gouni-Berthold","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.medcli.2019.11.003_bib0515","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2019.11.003_bib0520","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","article-title":"Volanesorsen: First global approval","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.medcli.2019.11.003_bib0525","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2019.11.003_bib0530","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2019.11.003_bib0535","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40265-014-0339-9","article-title":"Alipogene tiparvovec: A review of its use in adults with familial lipoprotein lipase deficiency","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.medcli.2019.11.003_bib0540","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1089\/hum.2018.007","article-title":"Gene therapy in lipoprotein lipase deficiency: Case report on the first patient treated with alipogene tiparvovec under daily practice conditions","volume":"29","author":"Kassner","year":"2018","journal-title":"Hum Gene Ther"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319307122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319307122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T16:56:40Z","timestamp":1586537800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775319307122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0025775319307122"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2019.11.003","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuevos tratamientos en la hipertrigliceridemia y en la hiperquilomicronemia","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2019.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}